- Home
- XFOR vs ACRS Comparison
XFOR vs ACRS Comparison
Compare XFOR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | ACRS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 314.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | XFOR | ACRS |
|---|---|---|
| Price | $4.43 | $3.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $28.50 | $9.75 |
| AVG Volume (30 Days) | 927.4K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,979,000.00 | $15,742,000.00 |
| Revenue This Year | $1,276.65 | N/A |
| Revenue Next Year | N/A | $6.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2925.74 | N/A |
| 52 Week Low | $1.35 | $1.05 |
| 52 Week High | $26.83 | $3.48 |
Technical Indicators
Market Signals| Indicator | XFOR | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 65.01 | 54.70 |
| Support Level | $3.50 | $2.78 |
| Resistance Level | $4.08 | $3.23 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 87.44 | 37.41 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.